Viewing Study NCT05888493


Ignite Creation Date: 2025-12-25 @ 1:16 AM
Ignite Modification Date: 2025-12-25 @ 11:25 PM
Study NCT ID: NCT05888493
Status: RECRUITING
Last Update Posted: 2025-10-29
First Post: 2023-05-01
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module